Pfizer Inc (PFE) 30.28 $PFE
Most active New York Stock Exchange-traded stocks
AP - Tue Nov 04, 5:02PM CST
NEW YORK (AP) — A look at New York Stock Exchange 10 most-active stocks at the close of trading:
TLM.TO: 6.10 (-0.82), F: 13.95 (-0.04), GE: 25.70 (unch), ABX.TO: 13.06 (-0.48), TLM: 5.36 (-0.74), K.TO: 2.36 (-0.16), ABX: 11.46 (-0.46), PFE: 30.28 (+0.09), HAL: 51.18 (-2.70), AKS: 6.34 (-1.09), BAC: 17.21 (-0.06), T: 34.79 (-0.05), LVLT: 47.25 (+0.58), S: 5.18 (-1.02), KGC: 2.07 (-0.15), TWTR: 40.90 (+0.69)
Final Glance: Pharmaceuticals companies
AP - Tue Nov 04, 5:02PM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
JNJ: 108.62 (+1.16), BAX: 68.45 (-1.23), PFE: 30.28 (+0.09), BMY: 57.84 (+0.04)
Midday Glance: Pharmaceuticals companies
AP - Tue Nov 04, 12:22PM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
JNJ: 108.62 (+1.16), BAX: 68.45 (-1.23), PFE: 30.28 (+0.09), BMY: 57.84 (+0.04)
Zoetis Q3 Earnings Beat Driven by Higher Livestock Sales - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 11:50AM CST
Zoetis' (ZTS) third-quarter 2014 earnings (excluding special items) of 41 cents per share were above the Zacks Consensus Estimate of 37 cents.
ZTS: 39.12 (+1.40), ENDP: 68.67 (+0.17), VRX: 133.61 (+0.76), PFE: 30.28 (+0.09)
Early Glance: Pharmaceuticals companies
AP - Tue Nov 04, 9:49AM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
JNJ: 108.62 (+1.16), BAX: 68.45 (-1.23), PFE: 30.28 (+0.09), BMY: 57.84 (+0.04)
Pharma Stocks on our Radar - Pfizer, Merck, Sanofi, Shire, and Zogenix
PR Newswire - Tue Nov 04, 7:55AM CST
Investor-Edge has initiated coverage on the following equities: Pfizer Inc. (NYSE: PFE), Merck and Company Inc. (NYSE: MRK), Sanofi (NYSE: SNY), Shire PLC (NASDAQ: SHPG), and Zogenix Inc. (NASDAQ: ZGNX). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Monday, November 03, 2014, ended on a mixed note as the Dow Jones Industrial Average finished at 17,366.24, down 0.14% and the NASDAQ Composite closed at 4,638.91, up 0.18%. The S&P 500 finished the session 0.01% lower at 2,017.81. During the trading session, seven out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 779.04, up 0.02%, with the index gaining 10.63% in the previous three months. Register for your complimentary reports on these five stocks at:
ZGNX: 1.40 (+0.04), SHPG: 195.62 (-0.87), MRK: 59.37 (+0.45), PFE: 30.28 (+0.09), SNY: 45.49 (-0.29)
Business Highlights
By The Associated Press - AP - Mon Nov 03, 5:03PM CST
___
JNJ: 108.62 (+1.16), UNH: 94.98 (+0.12), PFE: 30.28 (+0.09), DRI: 52.73 (+0.75)
Stock market's recovery is led by drugmakers
By STEVE ROTHWELL - AP - Mon Nov 03, 3:55PM CST
NEW YORK (AP) — For stocks, it's just what the doctor ordered.
UNH: 94.98 (+0.12), PFE: 30.28 (+0.09)
Minerals Technologies Digs Up A Winner With Buyout
at Investor's Business Daily - Mon Nov 03, 12:47PM CST
It didn't take long for a major buyout to have a positive impact on Minerals Technologies' financial results -- or for Wall Street to take note of the specialty mineral producer's blowout third quarter. Minerals Technologies (MTX) shares rose 20%...
SIAL: 135.14 (-0.27), PFE: 30.28 (+0.09), PX: 124.27 (-0.15), MTX: 75.74 (-0.17), APD: 133.67 (-1.72)
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Pipeline Review, H2 2014 - 27 Companies & 49 Drug Profiles
M2 - Mon Nov 03, 8:36AM CST
Research and Markets (http://www.researchandmarkets.com/research/3gdhmp/attention_deficit) has announced the addition of the "Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD) and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Involved in Therapeutics Development - DURECT Corporation - Eli Lilly and Company - Taisho Pharmaceutical Co., Ltd. - NeuroDerm Ltd. - Takeda Pharmaceutical Company Limited - Richter Gedeon Nyrt. - Pfizer Inc. - Purdue Pharma L.P. - Shire Plc - Vernalis plc - Collegium Pharmaceutical, Inc. - Hisamitsu Pharmaceutical Co., Inc. - Arbor Pharmaceuticals, LLC. - Curemark, LLC - Supernus Pharmaceuticals, Inc. - Intra-Cellular Therapies, Inc. - Tris Pharma, Inc. - Neos Therapeutics, Inc. - KemPharm, Inc. - Otsuka Holdings Co., Ltd. - Reviva Pharmaceuticals Inc. - Amarantus Bioscience Holdings, Inc. - Mnemosyne Pharmaceuticals, Inc. - Alcobra Ltd - Sunovion Pharmaceuticals Inc. - Signature Therapeutics, Inc - P2D Bioscience For more information visit http://www.researchandmarkets.com/research/3g...on_deficit
ADHD: 3.49 (-0.02), PFE: 30.28 (+0.09), SUPN: 7.83 (-0.07), LLY: 67.17 (+0.63), DRRX: 0.72 (+0.02), NDRM: (), SHPG: 195.62 (-0.87), ITCI: 15.06 (-0.10)
3 Dividend Stocks Better Than Pfizer, Inc.
Todd Campbell, The Motley Fool - Motley Fool - Sat Nov 01, 10:17AM CDT
Pfizer reported third-quarter earnings this week that were generally underwhelming. The drugmaker announced that its sales sagged 2.2% to $12.36 billion and its adjusted EPS fell similarly by 2% year over year in the quarter. Pfizer's...
NVO: 44.18 (+0.07), PFE: 30.28 (+0.09), AMGN: 160.41 (-1.15), NVS: 91.93 (+0.23)
Will Zoetis (ZTS) Pull a Surprise this Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 4:10PM CDT
Zoetis Inc. (ZTS) is scheduled to report third-quarter 2014 results before the opening bell on Nov 4.
ZTS: 39.12 (+1.40), ACT: 245.32 (-2.18), PFE: 30.28 (+0.09), HSP: 53.28 (+0.26)
Dow 30 Stock Roundup: DuPont, Merck, Pfizer Beat Estimates - Analyst Blog
Swarup Gupta - Zacks Investment Research - Fri Oct 31, 10:41AM CDT
The Dow experienced gains every day of the week, but for Wednesday, boosted by positive economic data and bullish earnings results.
MMM: 155.05 (+1.75), GS: 190.27 (-0.56), V: 242.97 (+1.43), IBM: 162.65 (-1.71), MRK: 59.37 (+0.45), PFE: 30.28 (+0.09), DD: 68.51 (-0.37), CAT: 98.61 (-1.61), PG: 88.64 (+1.26), MSFT: 47.57 (+0.13)
Stock Market News for October 31, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 9:10AM CDT
Benchmarks ended in the green zone on Thursday, banking on encouraging third quarter GDP numbers and upbeat quarterly results
JNJ: 108.62 (+1.16), NEE: 100.96 (+0.15), V: 242.97 (+1.43), GILD: 109.72 (-0.26), DUK: 82.23 (-0.15), EXC: 36.47 (+0.07), MRK: 59.37 (+0.45), PFE: 30.28 (+0.09), ABBV: 62.66 (-0.59), DTE: 82.39 (-0.41), SO: 46.94 (+0.17), MA: 83.99 (-0.14)
Pfizer's Trumenba Gains Accelerated Approval in the U.S. - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 30, 5:04PM CDT
Pfizer Inc.'s (PFE) Trumenba received accelerated FDA approval for prevention of invasive disease caused by Neisseria meningitidis serogroup B in people aged 10 - 25 years.
MNK: 94.09 (+0.66), ACT: 245.32 (-2.18), PFE: 30.28 (+0.09), MYL: 53.75 (+0.16)
Most active New York Stock Exchange-traded stocks
AP - Tue Nov 04, 5:02PM CST
NEW YORK (AP) — A look at New York Stock Exchange 10 most-active stocks at the close of trading:
TLM.TO: 6.10 (-0.82), F: 13.95 (-0.04), GE: 25.70 (unch), ABX.TO: 13.06 (-0.48), TLM: 5.36 (-0.74), K.TO: 2.36 (-0.16), ABX: 11.46 (-0.46), PFE: 30.28 (+0.09), HAL: 51.18 (-2.70), AKS: 6.34 (-1.09), BAC: 17.21 (-0.06), T: 34.79 (-0.05), LVLT: 47.25 (+0.58), S: 5.18 (-1.02), KGC: 2.07 (-0.15), TWTR: 40.90 (+0.69)
Final Glance: Pharmaceuticals companies
AP - Tue Nov 04, 5:02PM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
JNJ: 108.62 (+1.16), BAX: 68.45 (-1.23), PFE: 30.28 (+0.09), BMY: 57.84 (+0.04)
Midday Glance: Pharmaceuticals companies
AP - Tue Nov 04, 12:22PM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
JNJ: 108.62 (+1.16), BAX: 68.45 (-1.23), PFE: 30.28 (+0.09), BMY: 57.84 (+0.04)
Zoetis Q3 Earnings Beat Driven by Higher Livestock Sales - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 11:50AM CST
Zoetis' (ZTS) third-quarter 2014 earnings (excluding special items) of 41 cents per share were above the Zacks Consensus Estimate of 37 cents.
ZTS: 39.12 (+1.40), ENDP: 68.67 (+0.17), VRX: 133.61 (+0.76), PFE: 30.28 (+0.09)
Early Glance: Pharmaceuticals companies
AP - Tue Nov 04, 9:49AM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
JNJ: 108.62 (+1.16), BAX: 68.45 (-1.23), PFE: 30.28 (+0.09), BMY: 57.84 (+0.04)
Pharma Stocks on our Radar - Pfizer, Merck, Sanofi, Shire, and Zogenix
PR Newswire - Tue Nov 04, 7:55AM CST
Investor-Edge has initiated coverage on the following equities: Pfizer Inc. (NYSE: PFE), Merck and Company Inc. (NYSE: MRK), Sanofi (NYSE: SNY), Shire PLC (NASDAQ: SHPG), and Zogenix Inc. (NASDAQ: ZGNX). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Monday, November 03, 2014, ended on a mixed note as the Dow Jones Industrial Average finished at 17,366.24, down 0.14% and the NASDAQ Composite closed at 4,638.91, up 0.18%. The S&P 500 finished the session 0.01% lower at 2,017.81. During the trading session, seven out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 779.04, up 0.02%, with the index gaining 10.63% in the previous three months. Register for your complimentary reports on these five stocks at:
ZGNX: 1.40 (+0.04), SHPG: 195.62 (-0.87), MRK: 59.37 (+0.45), PFE: 30.28 (+0.09), SNY: 45.49 (-0.29)
Business Highlights
By The Associated Press - AP - Mon Nov 03, 5:03PM CST
___
JNJ: 108.62 (+1.16), UNH: 94.98 (+0.12), PFE: 30.28 (+0.09), DRI: 52.73 (+0.75)
Stock market's recovery is led by drugmakers
By STEVE ROTHWELL - AP - Mon Nov 03, 3:55PM CST
NEW YORK (AP) — For stocks, it's just what the doctor ordered.
UNH: 94.98 (+0.12), PFE: 30.28 (+0.09)
Minerals Technologies Digs Up A Winner With Buyout
at Investor's Business Daily - Mon Nov 03, 12:47PM CST
It didn't take long for a major buyout to have a positive impact on Minerals Technologies' financial results -- or for Wall Street to take note of the specialty mineral producer's blowout third quarter. Minerals Technologies (MTX) shares rose 20%...
SIAL: 135.14 (-0.27), PFE: 30.28 (+0.09), PX: 124.27 (-0.15), MTX: 75.74 (-0.17), APD: 133.67 (-1.72)
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Pipeline Review, H2 2014 - 27 Companies & 49 Drug Profiles
M2 - Mon Nov 03, 8:36AM CST
Research and Markets (http://www.researchandmarkets.com/research/3gdhmp/attention_deficit) has announced the addition of the "Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD) and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Involved in Therapeutics Development - DURECT Corporation - Eli Lilly and Company - Taisho Pharmaceutical Co., Ltd. - NeuroDerm Ltd. - Takeda Pharmaceutical Company Limited - Richter Gedeon Nyrt. - Pfizer Inc. - Purdue Pharma L.P. - Shire Plc - Vernalis plc - Collegium Pharmaceutical, Inc. - Hisamitsu Pharmaceutical Co., Inc. - Arbor Pharmaceuticals, LLC. - Curemark, LLC - Supernus Pharmaceuticals, Inc. - Intra-Cellular Therapies, Inc. - Tris Pharma, Inc. - Neos Therapeutics, Inc. - KemPharm, Inc. - Otsuka Holdings Co., Ltd. - Reviva Pharmaceuticals Inc. - Amarantus Bioscience Holdings, Inc. - Mnemosyne Pharmaceuticals, Inc. - Alcobra Ltd - Sunovion Pharmaceuticals Inc. - Signature Therapeutics, Inc - P2D Bioscience For more information visit http://www.researchandmarkets.com/research/3g...on_deficit
ADHD: 3.49 (-0.02), PFE: 30.28 (+0.09), SUPN: 7.83 (-0.07), LLY: 67.17 (+0.63), DRRX: 0.72 (+0.02), NDRM: (), SHPG: 195.62 (-0.87), ITCI: 15.06 (-0.10)
3 Dividend Stocks Better Than Pfizer, Inc.
Todd Campbell, The Motley Fool - Motley Fool - Sat Nov 01, 10:17AM CDT
Pfizer reported third-quarter earnings this week that were generally underwhelming. The drugmaker announced that its sales sagged 2.2% to $12.36 billion and its adjusted EPS fell similarly by 2% year over year in the quarter. Pfizer's...
NVO: 44.18 (+0.07), PFE: 30.28 (+0.09), AMGN: 160.41 (-1.15), NVS: 91.93 (+0.23)
Will Zoetis (ZTS) Pull a Surprise this Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 4:10PM CDT
Zoetis Inc. (ZTS) is scheduled to report third-quarter 2014 results before the opening bell on Nov 4.
ZTS: 39.12 (+1.40), ACT: 245.32 (-2.18), PFE: 30.28 (+0.09), HSP: 53.28 (+0.26)
Dow 30 Stock Roundup: DuPont, Merck, Pfizer Beat Estimates - Analyst Blog
Swarup Gupta - Zacks Investment Research - Fri Oct 31, 10:41AM CDT
The Dow experienced gains every day of the week, but for Wednesday, boosted by positive economic data and bullish earnings results.
MMM: 155.05 (+1.75), GS: 190.27 (-0.56), V: 242.97 (+1.43), IBM: 162.65 (-1.71), MRK: 59.37 (+0.45), PFE: 30.28 (+0.09), DD: 68.51 (-0.37), CAT: 98.61 (-1.61), PG: 88.64 (+1.26), MSFT: 47.57 (+0.13)
Stock Market News for October 31, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 9:10AM CDT
Benchmarks ended in the green zone on Thursday, banking on encouraging third quarter GDP numbers and upbeat quarterly results
JNJ: 108.62 (+1.16), NEE: 100.96 (+0.15), V: 242.97 (+1.43), GILD: 109.72 (-0.26), DUK: 82.23 (-0.15), EXC: 36.47 (+0.07), MRK: 59.37 (+0.45), PFE: 30.28 (+0.09), ABBV: 62.66 (-0.59), DTE: 82.39 (-0.41), SO: 46.94 (+0.17), MA: 83.99 (-0.14)
Pfizer's Trumenba Gains Accelerated Approval in the U.S. - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 30, 5:04PM CDT
Pfizer Inc.'s (PFE) Trumenba received accelerated FDA approval for prevention of invasive disease caused by Neisseria meningitidis serogroup B in people aged 10 - 25 years.
MNK: 94.09 (+0.66), ACT: 245.32 (-2.18), PFE: 30.28 (+0.09), MYL: 53.75 (+0.16)
